Monograph Details
|
|
Urogenital System
> Overactive bladder/enuresis
|
|
DETROL LA |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Muscarinic antagonist. |
| Generic Name |
|
Tolterodine tartrate 2mg, 4mg; ext-rel caps. |
| Also |
|
• DETROL
|
| Indications |
|
Overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence. |
| Children |
|
Not recommended. |
| Adults |
|
Swallow whole. 4 mg once daily; may decrease to 2 mg once daily. Concomitant CYP3A4 inhibitors, or significant renal or hepatic dysfunction: 2 mg once daily. |
| Contraindications |
|
Urinary or gastric retention. Uncontrolled narrow-angle glaucoma. |
| Precautions |
|
Bladder outflow obstruction. GI obstruction (eg, pyloric stenosis). Narrow-angle glaucoma. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Plasma levels increased by CYP3A4 inhibitors (eg, erythromycin). |
| Adverse Reactions |
|
Dry mouth/eyes, dyspepsia, fatigue, dizziness, sinusitis, abnormal vision, anxiety, dysuria, other anticholinergic effects. |
| How Supplied |
LA—30, 90, 500
Tabs—60, 500 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
